[go: up one dir, main page]

WO2017066557A1 - Polythérapie - Google Patents

Polythérapie Download PDF

Info

Publication number
WO2017066557A1
WO2017066557A1 PCT/US2016/057023 US2016057023W WO2017066557A1 WO 2017066557 A1 WO2017066557 A1 WO 2017066557A1 US 2016057023 W US2016057023 W US 2016057023W WO 2017066557 A1 WO2017066557 A1 WO 2017066557A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
poliovirus
checkpoint inhibitor
construct
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/057023
Other languages
English (en)
Inventor
Darell D. Bigner
Matthias Gromeier
Smita Nair
Vidyalakshmi Chandramohan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority to JP2018519304A priority Critical patent/JP6850290B2/ja
Priority to US15/768,147 priority patent/US10744170B2/en
Priority to CN201680060434.8A priority patent/CN108697788A/zh
Priority to EP16856268.4A priority patent/EP3362091A4/fr
Publication of WO2017066557A1 publication Critical patent/WO2017066557A1/fr
Anticipated expiration legal-status Critical
Priority to US16/990,036 priority patent/US20200368300A1/en
Priority to US18/545,176 priority patent/US20240415906A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention is related to the area of anti-tumor therapy. In particular, it relates to oncolytic virus anti-tumor therapy.
  • PVS-RIPO is an oncolytic poliovirus (PV) recombinant. It consists of the live attenuated type 1 (Sabin) PV vaccine containing a foreign internal ribosomal entry site (IRES) of human rhinovirus type 2 (HRV2).
  • IRES is a cis-acting genetic element located in the 5' untranslated region of the PV genome, mediating viral, m G-cap-independent translation. The virus has shown exciting signs of efficacy in humans. Nonetheless there is a continuing need in the art to identify and develop anti-cancer treatments that are more effective and that are effective for more humans, particularly for patients with brain tumors.
  • a method of treating a tumor in a patient is provided.
  • a chimeric poliovirus construct is administered to the patient.
  • the construct comprises a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5' untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame.
  • HRV2 human rhinovirus 2
  • IRS internal ribosome entry site
  • An immune checkpoint inhibitor is also administered to the patient, either at the same time or within about 30 days.
  • kits for treating a tumor.
  • the kit comprises a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5' untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame; and an immune checkpoint inhibitor.
  • HRV2 human rhinovirus 2
  • IRS internal ribosome entry site
  • a combination of a chimeric poliovirus construct and an immune checkpoint inhibitor for use as a medicament, or for use in treating a tumor wherein the chimeric poliovirus construct comprises a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5' untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame; and an immune checkpoint inhibitor.
  • HRV2 human rhinovirus 2
  • IRS internal ribosome entry site
  • Fig. 1 depicts experimental schema.
  • Fig. 2 shows results using four different tumor cell lines representing, breast, melanoma, and prostate cancers.
  • DCs were seeded in dishes. Supernatant from onco-lysate was added to DC cultures and incubated. Supernatant was then removed and DCs were washed. DNase I-treated peripheral blood mononuclear cells (PBMCs) were incubated at 37°C. Non-adherent cells were harvested and stimulated with DCs loaded with poliovirus-induced tumor lysate at a responder cell to stimulator DC ratio of 10: 1 in the presence of IL-7 in CTL stimulation media. T cells were harvested on day 12-14, counted and used as effector T cells in a europium-release CTL assay.
  • PBMCs peripheral blood mononuclear cells
  • Autologous DCs transfected with relevant and irrelevant tumor antigen-encoding mRNA were used as control targets.
  • mRNA-electroporated target cells were harvested, washed to remove all traces of media and labeled with europium (Eu).
  • original target cells (Suml49, MDAMB231, LNCaP, or DM6) were labeled with Eu.
  • T europium-labeled targets
  • E effector cells
  • % specific release [(experimental release - spontaneous release)/(total release - spontaneous release)] x 100.
  • Spontaneous release of the target cells was less than 25% of total release by detergent.
  • Spontaneous release of the target cells was determined by incubating the target cells in medium without T cells. All assays were done in triplicate, bars represent average % lysis and error bars denote SEM.
  • Fig. 3. shows results of in vivo testing in mouse tumor model using CT2A gliomas in C57B16 mice using a variety of treatments including a combined poliovirus and checkpoint inhibitor treatment analogous to the invention; both the mice and the CT2A cells express the human poliovirus receptor CD 155.
  • Results tumor volume over time with the following experimental treatments are shown in the top panel: Group I (blue): DMEM (vehicle to control for virus) + IgG (to control for anti-PDl); Group ⁇ (gray): single intra-tumoral injection of PVSRIPO + IgG; Group ⁇ (orange): single intra-tumoral injection of DMEM + anti-PDl; Group rV (gold): single intra-tumoral injection of PVSRIPO ("mRIPO”) + anti-PDl. Anti-PDl was given in three installments (days 3, 6, 9) by intraperitoneal injection. The three lower panels show tumor responses (tumor volume over time) in individual mice (each line a different mouse) in the treatment groups II-rV. DETAILED DESCRIPTION OF THE INVENTION
  • the inventors have developed a combination therapy regimen in which a viral construct and an immune checkpoint inhibitor are administered to humans. Because the poliovirus is a potential disease agent, extra precautions must be taken to ensure that disease-causing agents are not introduced to the subjects. Using good manufacturing procedures and purifications, a preparation was made that was sufficiently pure to permit introduction into humans.
  • Direct administration does not rely on the blood vasculature to access the tumor.
  • the preparation may be painted on the surface of the tumor, injected into the tumor, instilled in or at the tumor site during surgery, infused into the tumor via a catheter, etc.
  • One particular technique which may be used is convection enhanced delivery.
  • Immune checkpoint inhibitors which may be used according to the invention are any that disrupt the inhibitory interaction of cytotoxic T cells and tumor cells. These include but are not limited to anti-PD-1 antibody, anti-PD-Ll antibody, anti-CTLA4 antibody, anti- LAG-3 antibody, and/or anti-TIM-3 antibody. Approved checkpoint inhibitors in the U.S. include ipimilumab, pembrolizumab, and nivolumab. The inhibitor need not be an antibody, but can be a small molecule or other polymer. If the inhibitor is an antibody it can be a polyclonal, monoclonal, fragment, single chain, or other antibody variant construct.
  • Inhibitors may target any immune checkpoint known in the art, including but not limited to, CTLA-4, PDL1, PDL2, PD1, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD 160, CGEN- 15049, CHK 1, CHK2, A2aR, and the B-7 family of ligands. Combinations of inhibitors for a single target immune checkpoint or different inhibitors for different immune checkpoints may be used. Additionally, CSF- 1R blockade may be used in combination or as an alternative to immune checkpoint inhibitor(s), to ensure generation of potent and sustained immunity that effectively eliminates distant metastases and recurrent tumors. Antibodies specific for CSF-1R or drugs that inhibit or blockade CSF-IR may be used for this purpose, including but not limited to imactuzumab and AMG820.
  • the immune checkpoint inhibitor may be administered at the same time, before, or after the poliovirus. Typically the two agents will be administered within 30, 28, 21, 14, 7, 4, 2, or 1 day(s) of each other. The agents may be given repeatedly, either serially or in a cycle of first and second agents. It may be advantageous but not necessary for the vaccine to be administered prior to the checkpoint inhibitor. But the reverse order may also be used. Priming of a cytotoxic T lymphocyte response by the viral construct may take from about 5 to about 14 days. Administration of the checkpoint inhibitor may beneficially be commenced during or after the priming period.
  • Immune checkpoint inhibitors may be administered by any appropriate means known in the art for the particular inhibitor. These include intravenous, oral, intraperitoneal, sublingual, intrathecal, intracavitary, intramuscularly, and subcutaneously. Optionally, the immune checkpoint inhibitor may be administered in combination with the poliovirus agent.
  • Any human tumor can be treated, including both pediatric and adult tumors.
  • the tumor may be in any organ, for example, brain, prostate, breast, lung, colon, and rectum, Various types of tumors may be treated, including, for example, glioblastoma, medulloblastomas, carcinoma, adenocarcinoma, etc.
  • tumors include, adrenocortical carcinoma, anal cancer, appendix cancer, grade I (anaplastic) astrocytoma, grade II astrocytoma, grade ⁇ astrocytoma, grade IV astrocytoma, atypical teratoid/rhabdoid tumor of the central nervous system, basal cell carcinoma, bladder cancer, breast sarcoma, bronchial cancer, bronchoalveolar carcinoma, cervical cancer, craniopharyngioma, endometrial cancer, endometrial uterine cancer, ependymoblastoma, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, fibrous histiocytoma, gall bladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gest
  • patients may be stratified on the basis of NECL5 (poliovirus receptor) expression.
  • NECL5 poliovirus receptor
  • the NECL5 expression may guide the decision to treat or not treat with the chimeric poliovirus of the present invention.
  • the NECL5 expression may also be used to guide the aggressiveness of the treatment, including the dose, frequency, and duration of treatments.
  • Antibodies to NECL5 (CD155) are commercially available and may be used.
  • NECL5 RNA expression can also be assayed. See Hirota et al. Oncogene 24:2229-2235 (2005).
  • Treatment regimens may include, in addition to delivery of the chimeric poliovirus construct and immune checkpoint inhibitor combination, surgical removal of the tumor, surgical reduction of the tumor, chemotherapy, biological therapy, radiotherapy. These modalities are standard of care in many disease states, and the patient need not be denied the standard of care.
  • the chimeric poliovirus and immune checkpoint inhibitor combination may be administered before, during, or after the standard of care.
  • the chimeric poliovirus and immune checkpoint inhibitor combination may be administered after failure of the standard of care. When a combination is specified, it may be administered separately in time as two separate agents within a single combination regimen. Alternatively, the two (or more) agents may be administered in admixture.
  • Kits may comprise, in a single divided or undivided container, both the chimeric poliovirus construct PVSRIPO as well as a checkpoint inhibitor. They two may be in separate vessels or in a single vessel in admixture. Instructions for administration may be included. Optionally, an antibody for testing NECL5 expression in the patient is a component of the kit.
  • Applicants have found that the clinical pharmaceutical preparation of the chimeric poliovirus has admirable genetic stability and homogeneity. This is particularly advantageous as the poliovirus is known to be highly mutable both in culture and in natural biological reservoirs. Any suitable assay for genetic stability and homogeneity can be used.
  • One assay for stability involves testing for the inability to grow at 39.5 degrees C.
  • Another assay involves bulk sequencing.
  • Yet another assay involves testing for primate neuro virulence.
  • PVS-RIPO Animal tumor models.
  • An IND-directed efficacy trial of PVS-RIPO was conducted in the HTB-15 GBM xenograft model in athymic mice.
  • PVS-RIPO (from the clinical lot) was administered at the 'mouse- adjusted', FDA-approved max. starting dose [the FDA- approved max. starting dose (10e8 TCID) was adjusted for the reduced tumor size in mice (to 6.7xl0e6 TCID)]. Delivery mimicked the intended clinical route, i.e., slow intratumoral infusion. Under these conditions, PVS-RIPO induced complete tumor regress in all animals after 15 days. While virus was recovered from treated tumors until day 10, the levels were modest at best, indicating that direct viral tumor cell killing alone cannot account for the treatment effect.
  • the patient was re-scanned on 10/22 and there was a quantifiable radiographic response.
  • An MRI/PET overlay demonstrates the absence of signal from the general area of the tumor recurrence.
  • BrainLab iPlan Flow system is used to plan catheter trajectories based on predicted distributions using information obtained from a preoperative MRI.
  • This invention uses one mM of gadolinium as a surrogate tracer to identify the distribution of the poliovirus. This could be used for other drug infusions as well.
  • the gadolinium is co-infused with the drug and various MRI sequences are used to quantify the distribution.
  • epinephrine and diphenhydramine will be available and the neurologic status, oxygen saturation, and cardiac rhythm will be monitored. Drug infusion will occur in the Neuro-Surgical Intensive Care Unit (NSCU) so that all other emergency facilities will be available. Patients will be treated with a prophylactic antibiotic such as nafcillin, a second-generation cephalosporin or vancomycin starting with the induction of anesthesia for the catheter placement.
  • a prophylactic antibiotic such as nafcillin, a second-generation cephalosporin or vancomycin starting with the induction of anesthesia for the catheter placement.
  • a Medfusion 3500 infusion pump will be pre-programmed to a delivery rate of 500 ⁇ ⁇ .
  • the agent (which will be in a total volume of 10 mL to account for 'dead-space' of 3.3723 mL in the infusion system) will be loaded in a 20 mL syringe into the syringe pump at the initial onset to avoid any interruptions in the infusion.
  • the total amount of the inoculum delivered to the patient will be 3 mL.
  • the catheter itself (30 cm length, 1 mm interior diameter) cannot be preloaded with virus suspension. Therefore, the initial -250 of infusion will be preservative-free salinein the 'dead-space' of the indwelling catheter. To account for this, the infusion pump will be programmed for delivery of 3.250 mL. The infusion will be performed using a Medfusion 3500 (Medex, Inc., Duluth, GA) syringe infusion pump. The virus injection procedure will be completed within 6.5 hrs. The catheter will be removed immediately following the delivery of PVSRIPO.
  • Medfusion 3500 Medex, Inc., Duluth, GA
  • the infusion catheter (PIC 030) and infusion tubing ( ⁇ 400) will be supplied by Sophysa, Inc. (Crown Point, IN).
  • the Infusion Catheter Kit is a 30 cm clear, open-ended catheter (1.0 mm ID/2.0 mm OD) with 1 cm markings for 20 cm. The catheter comes with a 30 cm stainless steel stylet, a barbed female luer lock with cap and a stainless steel trocar.
  • the Infusion Tubing Kit consists of a 3-way stopcock connector with air filter, 4 m of microbore tubing with antisiphon valve, a red, vented cap and a white luer lock cap.
  • the catheter products are packaged sterile and non-pyrogenic and are intended for single (one-time) use only. The infusion will be performed using a Medfusion 3500 (Medex, Inc. Duluth, GA) syringe infusion pump.
  • the mechanism of immune checkpoint inhibitors is to release cytotoxic T cell function from events instigated by tumors that block their effector functions. Tumors engage a system of naturally existing 'brakes' that control cytotoxic T cells. To the tumor, this has the advantage of limiting the potential for the immune system to attack tumors that express mutant proteins and, therefore, represent a foreign signature. Immune checkpoint inhibitors reverse this tumor mechanism and release immune function.
  • PVSRIPO cytotoxic T cells
  • the activated dendritic cells were then co-cultivated with T cells (including CTLs) from the same human subject that donated the dendritic cells.
  • the co-cultured T cells were then co-cultivated with uninfected tumor cells from the same lines used for the infection step.
  • virus infection elicits a series of events that ultimately leads to the generation of a CTL response against the tumor.
  • This series of events can be enhanced synergistically with immune checkpoint inhibitors.
  • Confluent 10 cm dishes of Suml49, MDAMB231, LNCaP, or DM6 cells were infected with mock (DMEM) or PVSRIPO (MOI 0.1) in AIMV medium for 48 hours. Supernatants were collected and cell debris was removed by centrifugation. Frozen PBMCs were thawed, washed in PBS and resuspended at 2 x 10 cells in 30 ml AEVI-V media in T-150 tissue culture flasks (3). Cells were incubated for 1 h at 37°C. The nonadherent cells were harvested by rocking the flask from side to side to dislodge them.
  • the adherent cells were replenished with 30 ml AEVI-V supplemented with 800 U/ml human GM-CSF and 500 U/ml human IL-4, then incubated at 37°C.
  • DCs were harvested on day 6, by collecting all non-adherent cells, followed by a cold PBS wash. Cells that were still adherent were dissociated with cell dissociation buffer. DCs were washed in AIMV medium, counted and seeded in 35mm dishes at lxlO 6 cells per dish. Supernatant from onco-lysate was added to DC cultures and incubated for 24 hours. Supernatant was then removed and DCs were washed in AIMV medium.
  • PBMCs were thawed and resuspended in PBS and treated with DNase I at 200 U/ml for 20 min at 37°C.
  • DNase I-treated PBMCs were incubated for 1 h at 37°C, Non-adherent cells were harvested and stimulated with DCs loaded with poliovirus -induced tumor lysate at a responder cell to stimulator DC ratio of 10: 1 in the presence of 25 ng/ml IL-7.
  • All stimulations were done in RPMI 1640 with 10% FCS, 2 mM L-glutamine, 20 mM HEPES, 1 mM sodium pyruvate, 0.1 niM MEM non-essential amino acids, 100 IU/ml penicillin, 100 ⁇ g/ml streptomycin and 5 x 10 "5 M ⁇ -mercaptoethanol (CTL stimulation medium).
  • the responder T-cell concentration was 2 x 10 6 cells/ml.
  • IL-2 was added at 100 U/ml on day 3 and every 4-5 days for 12-14 days. T cells were maintained at 1-2 x 10 6 cells/ml in CTL stimulation medium.
  • T cells were harvested on day 12-14, counted and used as effector T cells in a europium-release CTL assay.
  • Autologous DCs transfected with tumor antigen- encoding mRNA were used as targets as controls.
  • mRNA- electroporated target cells (as designated in Figure 2) were harvested, washed to remove all traces of media and labeled with europium (Eu).
  • original target cells (Suml49, MDAMB231, LNCaP, or DM6) were labeled with Eu.
  • the Eu-labeling buffer (1 ml per target) contained 1 ml HEPES buffer (50 mM HEPES, 93 mM NaCl, 5 mM KC1, 2 mM MgCl 2 , pH 7.4), 10 ⁇ Eu (10 mM EuCl 3 .6H 2 0 in 0.01 N HC1), 5 ⁇ DTP A (100 mM diethylenetriamine pentaacetate in HEPES buffer) and 4 ⁇ DS (1% dextran- sulfate) (4) 5 x 10 6 target cells were resuspended in 1 ml of the europium-labeling buffer very gently and incubated on ice for 20 minutes.
  • HEPES buffer 50 mM HEPES, 93 mM NaCl, 5 mM KC1, 2 mM MgCl 2 , pH 7.4
  • 10 ⁇ Eu 10 mM EuCl 3 .6H 2 0 in 0.01 N HC1
  • % specific release [(experimental release - spontaneous release)/(total release - spontaneous release)] x 100.
  • Spontaneous release of the target cells was less than 25% of total release by detergent.
  • Spontaneous release of the target cells was determined by incubating the target cells in medium without T cells. All assays were done in triplicate, bars represent average % lysis and error bars denote SEM.
  • PVSRIPO antitumor efficacy may be aided by the virus' ability to elicit strongly immunogenic type 1 interferon (IFN) responses in infected tumor cells and in infected antigen-presenting cells (dendritic cells, macrophages, microglia).
  • IFN immunogenic type 1 interferon
  • type 1 IFN responses are highly desirable as mediators of immunotherapy, they also engage known immune checkpoints that can dampen the anti-neoplastic immune response elicited by PVSRIPO, e.g., PD-L1. Therefore, to maximize PVSRIPO immunotherapy, combination with immune checkpoint blockade may be indicated. This is evident in assays in immune-competent, syngeneic glioma tumor models (e.g., CT2A). See Martinez-Murillo et al., Histol. Histopathol. i2: 1309-26 (2007).
  • CT2A gliomas in C57B16 mice transgenic for the poliovirus receptor CD 155.
  • the CT2A cells used to initiate tumors were previously transduced with CD 155 (to enable PVSRIPO infection analogous to human cells).
  • Anti-PDl was given in three installments (days 3, 6, 9) by intraperitoneal injection. Results are shown in Figure 3; the top panel shows the group results and the bottom panels shows results for individual mice.
  • RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J Virol 80:6936-42.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation clinique chez l'homme d'une construction de poliovirus chimérique qui montre un excellent effet anti-tumoral. La combinaison avec des inhibiteurs du point de contrôle immunitaire augmente l'effet anti-tumoral. Des tumeurs de différents types sont sensibles à cette polythérapie, notamment mais non exclusivement le mélanome, le glioblastome, le carcinome à cellules rénales, le cancer de la prostate, le cancer du sein, le cancer du poumon, le médulloblastome, et le cancer colorectal.
PCT/US2016/057023 2015-10-15 2016-10-14 Polythérapie Ceased WO2017066557A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2018519304A JP6850290B2 (ja) 2015-10-15 2016-10-14 併用療法
US15/768,147 US10744170B2 (en) 2015-10-15 2016-10-14 Combination treatment
CN201680060434.8A CN108697788A (zh) 2015-10-15 2016-10-14 组合治疗
EP16856268.4A EP3362091A4 (fr) 2015-10-15 2016-10-14 Polythérapie
US16/990,036 US20200368300A1 (en) 2015-10-15 2020-08-11 Combination Treatment
US18/545,176 US20240415906A1 (en) 2015-10-15 2023-12-19 Combination Treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562242123P 2015-10-15 2015-10-15
US62/242,123 2015-10-15
US201662361725P 2016-07-13 2016-07-13
US62/361,725 2016-07-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/768,147 A-371-Of-International US10744170B2 (en) 2015-10-15 2016-10-14 Combination treatment
US16/990,036 Continuation US20200368300A1 (en) 2015-10-15 2020-08-11 Combination Treatment

Publications (1)

Publication Number Publication Date
WO2017066557A1 true WO2017066557A1 (fr) 2017-04-20

Family

ID=58518110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/057023 Ceased WO2017066557A1 (fr) 2015-10-15 2016-10-14 Polythérapie

Country Status (5)

Country Link
US (3) US10744170B2 (fr)
EP (1) EP3362091A4 (fr)
JP (3) JP6850290B2 (fr)
CN (1) CN108697788A (fr)
WO (1) WO2017066557A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195302A1 (fr) * 2018-04-02 2019-10-10 Duke University Traitement néoadjuvant du cancer
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
US11311628B2 (en) 2016-10-17 2022-04-26 Duke University Production of immunotoxin D2C7—(scdsFv)—PE38KDEL
US11506666B2 (en) 2016-10-06 2022-11-22 Duke University Detection of CD-155, the poliovirus receptor
US20220387529A1 (en) * 2019-11-04 2022-12-08 Duke University Treatment for primary and metastatic cancer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017019559B1 (pt) 2015-03-13 2020-08-04 Cytomx Therapeutics, Inc Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes
AU2018278327B2 (en) 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066983B2 (en) * 2008-03-14 2011-11-29 The Research Foundation Of State University Of New York Attenuated poliovirus
WO2014081937A2 (fr) * 2012-11-21 2014-05-30 Duke University Poliovirus oncolytique pour tumeurs humaines
WO2015069770A1 (fr) * 2013-11-05 2015-05-14 Cognate Bioservices, Inc. Combinaisons d'inhibiteurs de point de contrôle et d'agents thérapeutiques pour traiter un cancer
WO2015103602A1 (fr) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunothérapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
CA2940570A1 (fr) * 2014-02-27 2015-09-03 Viralytics Limited Therapie combinee pour le traitement du cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066983B2 (en) * 2008-03-14 2011-11-29 The Research Foundation Of State University Of New York Attenuated poliovirus
WO2014081937A2 (fr) * 2012-11-21 2014-05-30 Duke University Poliovirus oncolytique pour tumeurs humaines
WO2015069770A1 (fr) * 2013-11-05 2015-05-14 Cognate Bioservices, Inc. Combinaisons d'inhibiteurs de point de contrôle et d'agents thérapeutiques pour traiter un cancer
WO2015103602A1 (fr) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunothérapie

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
ANTONARAKIS, E.: "Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer", ASIAN JOURNAL OF ANDROLOGY, vol. 14, 2012, pages 520 - 521, XP055376095 *
CASTRICONI RA DAGAA DONDEROG ZONAPL POLIANI ET AL.: "NK cells recognize and kill human glioblastoma cells with stem cell-like properties", J IMMUNOL, vol. 182, 2009, pages 3530 - 39
DE BREYNE SY YUA UNBEHAUNTV PESTOVACU HELLEN: "Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites", PROC NATL ACAD SCI USA, vol. 106, 2009, pages 9197 - 202
DOBRIKOVA EYC GOETZRW WALTERSSK LAWSONJO PEGGINS ET AL.: "Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis", J VIROL, vol. 86, pages 2750 - 9
DOBRIKOVA EYT BROADTJ POILEY-NELSONX YANGG SOMAN ET AL.: "Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype", MOL THER, vol. 16, 2008, pages 1865 - 72, XP055263256, DOI: 10.1038/mt.2008.184
ERICKSON BMNL THOMPSONDC HIXSON: "Tightly regulated induction of the adhesion molecule necl-5/CD155 during rat liver regeneration and acute liver injury", HEPATOLOGY, vol. 43, 2006, pages 325 - 34, XP071560855, DOI: 10.1002/hep.21021
GOETZ CE DOBRIKOVAM SHVEYGERTM DOBRIKOVM GROMEIER: "Oncolytic poliovirus against malignant glioma", FUTURE VIROL, vol. 6, 2011, pages 1045 - 58, XP055263250, DOI: 10.2217/fvl.11.76
GOETZ, CRG EVERSONL ZHANGM GROMEIER: "MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus", MOL THER, vol. 18, 2010, pages 1937 - 46
GROMEIER MB BOSSERTM ARITAA NOMOTOE WIMMER: "Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence", J VIROL, vol. 73, 1999, pages 958 - 64
GROMEIER MD SOLECKIDD PATELE WIMMER: "Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis", VIROLOGY, vol. 273, 2000, pages 248 - 57, XP004436228, DOI: 10.1006/viro.2000.0418
GROMEIER ML ALEXANDERE WIMMER.: "Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants", PROC NATL ACAD SCI USA, vol. 93, 1996, pages 2370 - 5
GROMEIER MS LACHMANNMR ROSENFELDPH GUTINE WIMMER: "Intergeneric poliovirus recombinants for the treatment of malignant glioma", PROC NATL ACAD SCI USA, vol. 97, 2000, pages 6803 - 8, XP002259551, DOI: 10.1073/pnas.97.12.6803
HIROTA ET AL., ONCOGENE, vol. 24, 2005, pages 2229 - 2235
IWASAKI AR WELKERS MUELLERM LINEHANA NOMOTO ET AL.: "Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection", J INFECT DIS, vol. 186, 2002, pages 585 - 92
JOSHI SS KAURAJ REDIGK GOLDSBOROUGHK DAVID ET AL.: "Type I IFN-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses", PROC NATL ACAD SCI USA, vol. 106, pages 12097 - 102
MARTINEZ-MURILLO ET AL., HISTOL. HISTOPATHOL., vol. 12, 2007, pages 1309 - 26
MASSON DA JARRYB BAURYP BLANCHARDIEC LABOISSE ET AL.: "Overexpression of the CD155 gene in human colorectal carcinoma", GUT, vol. 49, 2001, pages 236 - 40, XP008022982, DOI: 10.1136/gut.49.2.236
MERRILL MKEY DOBRIKOVAM GROMEIER.: "Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76", J VIROL, vol. 80, 2006, pages 3147 - 56
MERRILL MKG BERNHARDTJH SAMPSONCJ WIKSTRANDDD BIGNER ET AL.: "Poliovirus receptor CD155-targeted oncolysis of glioma", NEURO-ONCOL, vol. 6, 2004, pages 208 - 17, XP008035764, DOI: 10.1215/S1152851703000577
MERRILL MKM GROMEIER: "The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site", J VIROL, vol. 80, 2006, pages 6936 - 42
NAKAI RY MANIWAY TANAKAW NISHIOM YOSHIMURA ET AL.: "Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma", CANCER SCI, vol. 101, 2010, pages 1326 - 30
NEPLIOUEVA VEY DOBRIKOVAN MUKHERJEEJD KEENEM GROMEIER.: "Tissue type-specific expression of the DRBP76 and genome-wide elucidation of its target mRNAs", PLOS ONE, vol. 5, 2010, pages 1710
OCHIAI HSA CAMPBELLGE ARCHERTA CHEWNINGE DRAGUNSKY ET AL.: "Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus", CLIN CAN RES, vol. 12, 2006, pages 1349 - 54, XP055263301, DOI: 10.1158/1078-0432.CCR-05-1595
OCHIAI HSA MOOREGE ARCHERT OKAMURATA CHEWNING ET AL.: "Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus", CLIN CAN RES, vol. 10, 2004, pages 4831 - 8
See also references of EP3362091A4
TAKAI YJ MIYOSHIW IKEDAH OGITA: "Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation", NAT REV MOL CELL BIOL, vol. 9, 2008, pages 603 - 15
TOYODA HJ YINS MUELLERE WIMMERJ CELLO: "Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model", CANCER RES, vol. 67, 2007, pages 2857 - 64, XP002633529, DOI: 10.1158/0008-5472.CAN-06-3713
WAHID RMJ CANNONM CHOW.: "Dendritic cells and macrophages are productively infected by poliovirus", J VIROL, vol. 79, 2005, pages 401 - 9

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
US11506666B2 (en) 2016-10-06 2022-11-22 Duke University Detection of CD-155, the poliovirus receptor
US11311628B2 (en) 2016-10-17 2022-04-26 Duke University Production of immunotoxin D2C7—(scdsFv)—PE38KDEL
WO2019195302A1 (fr) * 2018-04-02 2019-10-10 Duke University Traitement néoadjuvant du cancer
CN112118853A (zh) * 2018-04-02 2020-12-22 杜克大学 新辅助癌症疗法
JP2021520368A (ja) * 2018-04-02 2021-08-19 デューク ユニバーシティ ネオアジュバントがん治療
JP7550449B2 (ja) 2018-04-02 2024-09-13 デューク ユニバーシティ ネオアジュバントがん治療
AU2019247039B2 (en) * 2018-04-02 2025-10-16 Duke University Neoadjuvant cancer treatment
US20220387529A1 (en) * 2019-11-04 2022-12-08 Duke University Treatment for primary and metastatic cancer

Also Published As

Publication number Publication date
EP3362091A1 (fr) 2018-08-22
EP3362091A4 (fr) 2019-04-24
JP2018530584A (ja) 2018-10-18
JP2020183447A (ja) 2020-11-12
US20200368300A1 (en) 2020-11-26
US20240415906A1 (en) 2024-12-19
CN108697788A (zh) 2018-10-23
JP2022183342A (ja) 2022-12-08
US20180296614A1 (en) 2018-10-18
US10744170B2 (en) 2020-08-18
JP6850290B2 (ja) 2021-03-31

Similar Documents

Publication Publication Date Title
US11813298B2 (en) Oncolytic poliovirus for human tumors
US20240415906A1 (en) Combination Treatment
AU2019247039B2 (en) Neoadjuvant cancer treatment
CA3017631C (fr) Traitement anticancereux sequentiel
HK40056896A (en) Oncolytic poliovirus for human tumors
HK1211487B (en) Oncolytic poliovirus for human tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16856268

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2018519304

Country of ref document: JP

Ref document number: 15768147

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016856268

Country of ref document: EP